The impact of cannabinoids on inflammation, HIV viral load and symptoms of distress among persons living with HIV

大麻素对艾滋病毒感染者炎症、艾滋病毒病毒载量和痛苦症状的影响

• 批准号: 10646317
• 负责人: Chukwuemeka Nkemakonam Okafor
• 金额: $ 11.89万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10646317
• 关键词: Abstinence; Address; Anti-Inflammatory Agents; Anxiety; Applications Grants; Behavior Therapy; Behavioral Sciences; Biological Markers; C-reactive protein; Cannabidiol; Cannabinoids; Cannabis; Cannabis policy; Clinic; Clinical; Clinical Trials; Cohort Studies; County; Data; Data Analyses; Data Collection; Distress; Drug usage; Educational workshop; Enrollment; Epidemiology; Ethics; Feasibility Studies; Goals; HIV; Health; Inflammation; Inflammatory; Interleukin-6; Knowledge; Laws; Link; Longitudinal cohort study; Los Angeles; Measures; Medical; Mental Depression; Mental Health; Mentored Research Scientist Development Award; Mentors; Moods; National Institute of Drug Abuse; Outcome; Participant; Persons; Policies; Prevalence; Prevention Research; Professional Competence; Property; Public Health; Recreation; Research; Research Activity; Research Project Grants; Role; Services; Symptoms; TNF gene; Therapeutic; Training; United States; Urine; Viral; Viral Load result; Vulnerable Populations; Withdrawal Symptom; Work; addiction; anxiety symptoms; career; career development; clinical trial analysis; contingency management; depressive symptoms; design; drug abuse prevention; longitudinal, prospective study; marijuana use; men; men of color; mental set; multidisciplinary; novel; policy implication; programs; prospective; reduce symptoms; research and development; secondary analysis; sex; skill acquisition; skills; sound; symposium; urinary

7. PROJECT ABSTRACT This Mentored Research Scientist Development Award (K01) will provide Dr. Chukwuemeka N. Okafor with training and expertise needed to facilitate his transition toward research independence in HIV and drug use prevention research. Dr. Okafor’s proposed training plan is designed to build upon his previous work in HIV and drug use epidemiology to increase his knowledge and expertise in: (1) the design, implementation and analysis of clinical trials and behavioral interventions for drug use prevention in the context of HIV (2) addiction research and research that integrates behavioral science and biological markers in the context of drug use and HIV (3) training in the ethical conduct of research and (4) career skills necessary for academic research. Dr. Okafor will achieve these training goals via didactic coursework, directed readings, workshops, scientific conferences, fieldwork and mentoring from an expert multidisciplinary panel of mentors led by Dr. Steve Shoptaw (primary mentor). The proposed research activities addresses an important public health issue regarding the impact of cannabis on health outcomes among persons living with HIV (PLWH). Majority of the few studies of the consequences of cannabis use in PLWH have produced mixed findings. Potential explanations for lack of clear evidence of the health consequences of cannabis might be due to the different active constituents (cannabinoids) in the cannabis products used. Tetrahydrocannabidiol (THC) and cannabidiol (CBD) are the most frequently studied cannabinoids and growing evidence suggest that they have opposing effects on symptoms of distress (e.g. depression and anxiety) and HIV relevant health outcomes (inflammation and HIV viral load). Specifically, THC is associated with mood altering and negative health effects, while CBD does not alter mood and may have therapeutic properties. Therefore, whether quantifiable biomarkers of THC and CBD in PLWH who use cannabis can provide clarification on the consequences of cannabinoids in PLWH has not being determined. The proposed project will employ two approaches to address this question including a secondary analysis of existing data from a cohort study and a pilot feasibility study involving PLWH who use cannabis. Specifically, the proposed project aims to: 1) determine relationships between measured concentrations of THC and CBD in urine with biomarkers of inflammation and HIV viral load in PLWH, (2) investigate associations between measured concentrations of THC and CBD in urine with symptoms of distress among PLWH and 3) To determine feasibility of and impact of a 28-day cannabis abstinence based contingency management (CM) program on changes in symptoms of distress, inflammation and HIV viral load. Completing the proposed project will provide an excellent pedestal for Dr. Okafor to transition into an independent research career.

7。项目摘要 这项指导的研究科学家发展奖（K01）将为Chukwuemeka N. Okafor博士提供 培训和专业知识需要促进他向艾滋病毒和吸毒的研究独立性过渡 预防研究。 Okafor博士提议的培训计划旨在以他先前在艾滋病毒中的作品为基础 药物使用流行病学来提高他的知识和专业知识：（1）设计，实施和 艾滋病毒背景下的临床试验和预防药物使用的行为干预措施分析（2）成瘾 研究和研究在毒品使用和 艾滋病毒（3）培训研究的道德行为以及（4）学术研究所需的职业技能。博士 OKAFOR将通过教学课程，定向阅读，讲习班，科学实现这些培训目标 由史蒂夫博士领导的专家跨学科小组的会议，实地调查和心理 Shoptaw（主要导师）。拟议的研究活动解决了一个重要的公共卫生问题 关于大麻对艾滋病毒（PLWH）患者的健康结果的影响。大部分 关于PLWH中大麻使用后果的研究很少产生混合发现。潜在的 缺乏明确证据的大麻健康后果的解释可能是由于不同的 活跃的大麻产品中的活性构成（大麻素）。四氢大麻二酚（THC）和 大麻二酚（CBD）是最常研究的大麻素，越来越多的证据表明它们具有 对遇险症状（例如抑郁和动画）和艾滋病毒相关的健康结果的影响 （炎症和HIV病毒负荷）。具体而言，THC与改变情绪和负面健康有关 效果，而CBD不会改变情绪，并且可能具有治疗特性。因此，是否可量化 使用大麻的PLWH的THC和CBD的生物标志物可以澄清有关的后果 尚未确定PLWH中的大麻素。拟议的项目将采用两种方法 解决此问题，包括对队列研究中现有数据的次要分析和飞行员可行性 涉及使用大麻的PLWH的研究。具体而言，拟议的项目的目的是：1）确定关系 尿液中的尿液中的THC和CBD浓度和HIV病毒的生物标志物之间 PLWH中的负载，（2）研究尿液中测得的THC和CBD浓度与 PLWH和3）确定28天大麻的可行性和影响的症状 基于禁欲的应急管理（CM）计划，遇到症状，炎症的症状变化 和HIV病毒负荷。完成拟议的项目将为Okafor博士提供一个绝佳的基座 过渡到独立研究职业。